|
1
|
Arnold M, Karim-Kos HE, Coebergh JW,
Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D and
Soerjomataram I: recent trends in incidence of five common cancers
in 26 European countries since 1988: Analysis of the European
Cancer Observatory. Eur J Cancer. 51:1164–1187. 2015. View Article : Google Scholar
|
|
2
|
Luengo-Fernandez R, Leal J, Gray A and
Sullivan R: Economic burden of cancer across the European Union: A
population-based cost analysis. Lancet Oncol. 14:1165–1174. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Sakr WA, Haas GP, Cassin BF, Pontes JE and
Crissman JD: The frequency of carcinoma and intraepithelial
neoplasia of the prostate in young male patients. J Urol.
150:379–385. 1993.PubMed/NCBI
|
|
4
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Haas GP, Delongchamps N, Brawley OW, Wang
CY and de la Roza G: The worldwide epidemiology of prostate cancer:
Perspectives from autopsy studies. Can J Urol. 15:3866–3871.
2008.PubMed/NCBI
|
|
6
|
Walsh PC, Partin AW and Epstein JI: Cancer
control and quality of life following anatomical radical retropubic
prostatectomy: Results at 10 years. J Urol. 152:1831–1836.
1994.PubMed/NCBI
|
|
7
|
Watson RB, Civantos F and Soloway MS:
Positive surgical margins with radical prostatectomy: Detailed
pathological analysis and prognosis. Urology. 48:80–90. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng L, Darson MF, Bergstralh EJ, Slezak
J, Myers RP and Bostwick DG: Correlation of margin status and
extraprostatic extension with progression of prostate carcinoma.
Cancer. 86:1775–1782. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vesely S, Jarolim L, Duskova K, Schmidt M,
Dusek P and Babjuk M: The use of early postoperative
prostate-specific antigen to stratify risk in patients with
positive surgical margins after radical prostatectomy. BMC Urol.
14:792014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Aebersold R, Anderson L, Caprioli R,
Druker B, Hartwell L and Smith R: Perspective: A program to improve
protein biomarker discovery for cancer. J Proteome Res.
4:1104–1109. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bergman N and Bergquist J: Recent
developments in proteomic methods and disease biomarkers. Analyst
(Lond). 139:3836–3851. 2014. View Article : Google Scholar
|
|
12
|
Heger Z, Kominkova M, Cernei N, Krejcova
L, Kopel P, Zitka O, Adam V and Kizek R: Fluorescence resonance
energy transfer between green fluorescent protein and doxorubicin
enabled by DNA nanotechnology. Electrophoresis. 35:3290–3301. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Vyslouzilova L, Krizkova S, Anyz J, Hynek
D, Hrabeta J, Kruseova J, Eckschlager T, Adam V, Stepankova O and
Kizek R: Use of brightness wavelet transformation for automated
analysis of serum metallothioneins- and zinc-containing proteins by
western blots to subclassify childhood solid tumours.
Electrophoresis. 34:1637–1648. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Shevchenko A, Tomas H, Havlis J, Olsen JV
and Mann M: In-gel digestion for mass spectrometric
characterization of proteins and proteomes. Nat Protoc.
1:2856–2860. 2006. View Article : Google Scholar
|
|
15
|
Oh J, Pyo JH, Jo EH, Hwang SI, Kang SC,
Jung JH, Park EK, Kim SY, Choi JY and Lim J: Establishment of a
near-standard two-dimensional human urine proteomic map.
Proteomics. 4:3485–3497. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rehman I, Azzouzi AR, Catto JWF, Allen S,
Cross SS, Feeley K, Meuth M and Hamdy FC: Proteomic analysis of
voided urine after prostatic massage from patients with prostate
cancer: A pilot study. Urology. 64:1238–1243. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye B, Skates S, Mok SC, Horick NK,
Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS,
et al: Proteomic-based discovery and characterization of
glycosylated eosinophil-derived neurotoxin and COOH-terminal
osteopontin fragments for ovarian cancer in urine. Clin Cancer Res.
12:432–441. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Botezatu I, Serdyuk O, Potapova G,
Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A,
Narimanov M, et al: Genetic analysis of DNA excreted in urine: A
new approach for detecting specific genomic DNA sequences from
cells dying in an organism. Clin Chem. 46:1078–1084.
2000.PubMed/NCBI
|
|
19
|
Oh J, Wilson L, Kirk M, Deshane J and Kim
H: Proteomics of normal human and prostate cancer urines. FASEB J.
17:759.7572003.
|
|
20
|
Kshirsagar B and Wiggins RC: A map of
urine proteins based on one-dimensional SDS-polyacrylamide gel
electrophoresis and western blotting using one microliter of
unconcentrated urine. Clin Chim Acta. 158:13–22. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zaragoza C, Barrera R, Centeno F, Tapia JA
and Mañe MC: Canine pyometra: A study of the urinary proteins by
SDS-PAGE and western blot. Theriogenology. 61:1259–1272. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Le Bricon T, Erlich D, Bengoufa D,
Dussaucy M, Garnier JP and Bousquet B: Sodium dodecyl
sulfate-agarose gel electrophoresis of urinary proteins:
Application to multiple myeloma. Clin Chem. 44:1191–1197.
1998.PubMed/NCBI
|
|
23
|
Marshall T and Williams KM: High
resolution two-dimensional electrophoresis of human urinary
proteins. Anal Chim Acta. 372:147–160. 1998. View Article : Google Scholar
|
|
24
|
Thongboonkerd V, McLeish KR, Arthur JM and
Klein JB: Proteomic analysis of normal human urinary proteins
isolated by acetone precipitation or ultracentrifugation. Kidney
Int. 62:1461–1469. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Adachi J, Kumar C, Zhang Y, Olsen JV and
Mann M: The human urinary proteome contains more than 1500
proteins, including a large proportion of membrane proteins. Genome
Biol. 7:R802006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Day ML, Zhao X, Vallorosi CJ, Putzi M,
Powell CT, Lin C and Day KC: E-cadherin mediates
aggregation-dependent survival of prostate and mammary epithelial
cells through the retinoblastoma cell cycle control pathway. J Biol
Chem. 274:9656–9664. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Cheng L, Nagabhushan M, Pretlow TP, Amini
SB and Pretlow TG: Expression of E-cadherin in primary and
metastatic prostate cancer. Am J Pathol. 148:1375–1380.
1996.PubMed/NCBI
|
|
28
|
Umbas R, Isaacs WB, Bringuier PP,
Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM and Schalken
JA: Decreased E-cadherin expression is associated with poor
prognosis in patients with prostate cancer. Cancer Res.
54:3929–3933. 1994.PubMed/NCBI
|
|
29
|
Giroldi LA and Schalken JA: Decreased
expression of the intercellular adhesion molecule E-cadherin in
prostate cancer: Biological significance and clinical implications.
Cancer Metastasis Rev. 12:29–37. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shimamura T, Sakamoto M, Ino Y, Sato Y,
Shimada K, Kosuge T, Sekihara H and Hirohashi S: Dysadherin
overexpression in pancreatic ductal adenocarcinoma reflects tumor
aggressiveness: Relationship to e-cadherin expression. J Clin
Oncol. 21:659–667. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Duffy MJ: Tumor markers in clinical
practice: A review focusing on common solid cancers. Med Princ
Pract. 22:4–11. 2013. View Article : Google Scholar
|
|
32
|
Gutman EB, Sproul EE and Gutman AB:
Significance of increased phosphatase activity of bone at the site
of osteoplastic metastases secondary to carcinoma of the prostate
gland. Am J Cancer. 28:485–495. 1936. View Article : Google Scholar
|
|
33
|
Wang MC, Papsidero LD, Kuriyama M,
Valenzuela LA, Murphy GP and Chu TM: Prostate antigen: A new
potential marker for prostatic cancer. Prostate. 2:89–96. 1981.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Morikawa W, Yamamoto K, Ishikawa S,
Takemoto S, Ono M, Fukushi J, Naito S, Nozaki C, Iwanaga S and
Kuwano M: Angiostatin generation by cathepsin D secreted by human
prostate carcinoma cells. J Biol Chem. 275:38912–38920. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lim JTE, Mansukhani M and Weinstein IB:
Cyclin-dependent kinase 6 associates with the androgen receptor and
enhances its transcriptional activity in prostate cancer cells.
Proc Natl Acad Sci USA. 102:5156–5161. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Choi YJ and Anders L: Signaling through
cyclin D-dependent kinases. Oncogene. 33:1890–1903. 2014.
View Article : Google Scholar
|
|
37
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Finn RS, Dering J, Conklin D, Kalous O,
Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tan MHE, Li J, Xu HE, Melcher K and Yong
EL: Androgen receptor: Structure, role in prostate cancer and drug
discovery. Acta Pharmacol Sin. 36:3–23. 2015. View Article : Google Scholar :
|
|
40
|
Sardana G, Marshall J and Diamandis EP:
Discovery of candidate tumor markers for prostate cancer via
proteomic analysis of cell culture-conditioned medium. Clin Chem.
53:429–437. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Inohara H, Akahani S, Koths K and Raz A:
Interactions between galectin-3 and Mac-2-binding protein mediate
cell-cell adhesion. Cancer Res. 56:4530–4534. 1996.PubMed/NCBI
|
|
42
|
Hu J, He J, Kuang Y, Wang Z, Sun Z, Zhu H
and Liu X: Expression and significance of 90k/Mac-2BP in prostate
cancer. Exp Ther Med. 5:181–184. 2013.
|
|
43
|
Srirajaskanthan R, Caplin ME, Waugh MG,
Watkins J, Meyer T, Hsuan JJ and Beaumont NJ: Identification of
Mac-2-binding protein as a putative marker of neuroendocrine tumors
from the analysis of cell line secretomes. Mol Cell Proteomics.
9:656–666. 2010. View Article : Google Scholar :
|
|
44
|
Scanlan MJ, Simpson AJG and Old LJ: The
cancer/testis genes: Review, standardization, and commentary.
Cancer Immun. 4:1–15. 2004.PubMed/NCBI
|
|
45
|
Gure AO, Chua R, Williamson B, Gonen M,
Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, et
al: Cancer-testis genes are coordinately expressed and are markers
of poor outcome in non-small cell lung cancer. Clin Cancer Res.
11:8055–8062. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Andrade VCC, Vettore AL, Almeida MSS, et
al: Prognostic impact of cancer testis antigens expression in
advanced stage multiple myeloma patients. Blood. 110:257B.
2007.
|
|
47
|
Marcovich R, Wojno KJ, Wei JT, Rubin MA,
Montie JE and Sanda MG: Bladder neck-sparing modification of
radical prostatectomy adversely affects surgical margins in
pathologic T3a prostate cancer. Urology. 55:904–908. 2000.
View Article : Google Scholar : PubMed/NCBI
|
